Executive Leadership

Usama Malik

Chief Financial Officer, Chief Business Officer

As Chief Financial Officer, Usama is responsible for maximizing the value of Immunomedics, while ensuring prudent and compliant management of the Company’s financial resources. As the Chief Business Officer, he also leads the organization’s corporate business functions, including Business Development, Corporate Strategy, Information Technology, and Corporate Affairs. He joined Immunomedics in 2017.

Usama has over 25 years of experience in the technology, telecoms, and healthcare industries in key leadership roles ranging from corporate strategy, mergers and acquisitions, venture investing, product development, and general management. He has worked on large-scale transformations across Fortune 500 companies, while helping to scale and grow numerous venture-backed and mid-sized organizations. He has led key strategic efforts to bolster company balance sheets, take out costs, generate new revenue streams, raise capital, and lead multibillion-dollar M&A transactions.

  • M.B.A. Finance, Strategy, Entrepreneurship, INSEAD
  • B.Sc., Electrical Engineering, University of Maryland at College Park

“I truly love having the opportunity to work on groundbreaking science that can have a profound impact on people’s health and quality of life. Importantly, I cherish the moments I have with my colleagues, with clinicians and healthcare providers, and with people with hard-to-treat cancers and their caregivers to dramatically reframe what therapeutic innovation and patient care means.”

Loretta Itri, M.D., F.A.C.P.

Chief Medical Officer

Dr. Loretta Itri leads all research and clinical development, regulatory, safety and medical affairs activities. She joined Immunomedics in February 2020 as the Chief Medical Officer.

Dr. Itri has decades of experience and a strong track record of bringing innovative drugs to market for multiple biopharma organizations. She was most recently the Executive Vice President of Global Health Sciences & Regulatory Affairs at The Medicines Company where she oversaw the development and regulatory approval of a variety of products. Previously, she was president of Pharmaceutical Development and CMO at Genta, Inc., involved in the development of therapeutic agents for breast cancer and chronic lymphocytic leukemia.

Prior to that, Dr. Itri served as Senior Vice President of Medical and Regulatory Affairs at Johnson & Johnson’s Pharmaceutical Research Institute, where she oversaw the development and approval of several products, including Procrit, Cladribine, and Tramadol. In addition, she served as Senior Vice President of Clinical Affairs and CMO for Ortho Biotech Inc. Dr. Itri began her career at Hoffmann-La Roche, as Assistant Vice President of Clinical Development in immunology and oncology.

Dr. Itri received her M.D. from New York Medical College, completed her medical residency at SUNY-Stony Brook and her fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center where she was an adjunct attending physician for more than 15 years. Dr. Itri has served as a member of the National Cancer Institute Board of Scientific Counselors and has published extensively on the development of therapeutic agents.

  • New York Medical College – M.D.
  • SUNY-Stony Brook (Residency)
  • Memorial Sloane-Kettering Cancer Center (Fellowship)

“The people who work in oncology are quite special. I’m very impressed by the dedication, resilience and sheer tenacity of our team at Immunomedics. Our science has the potential to help many people; our team never gives up because we know our work is important to patients.”

Brendan Delaney

Chief Commercial Officer

Brendan brings deep commercial strategy and product launch experience to his role leading our commercial organization. As the first commercial hire at Immunomedics in November 2017, Brendan led the buildout of the marketing, sales, market access and commercial operations teams.

Brendan has more than 25 years of global pharmaceutical and biotechnology experience, most recently serving as Vice President of U.S. Commercial Hematology-Oncology at Celgene Corporation. Prior to joining Celgene, Brendan held various commercial roles at both Novartis Oncology and Genentech. Brendan has led several successful product launches for blockbuster brands across both oncology and hematology. His deep commercial background and business acumen are helping to drive Immunomedics’ leadership in oncology.

  • M.B.A., Finance, NYU Stern School of Business
  • B.S. with High Honors, Biological Sciences, Rutgers University

“I joined Immunomedics because I believed in the impact that Sacituzumab Govitecan, and our broader ADC platform, could have on the lives of so many cancer patients. We have made great progress, but there is much more work to do in order to realize the potential of our great science.”

Bryan Ball

Chief Quality Officer

As the Chief Quality Officer, Bryan has responsibility for the global quality function ensuring our products are safe and effective and leads the organization in the development and deployment of modern quality systems and processes. Bryan oversees the execution of the quality strategy, balancing immediate business needs with long-term investment in systems, processes and people. He joined Immunomedics in February 2019.

With more than 24 years of experience leading and improving Quality, Operations, and Compliance functions in the Pharmaceutical, Biopharmaceutical and Medical Device industries Bryan has dedicated his career to preserving and improving patient’s health outcomes. Bryan has a proven track record of transformational leadership, providing critical products to market while guiding organizations through organic and inorganic growth, restructuring to gain a competitive edge and building cultures with Quality as a strategic business partner. Prior to Immunomedics Bryan held executive roles with Mallinckrodt, Boehringer-Ingelheim and Sigma-Aldrich.

  • MBA, Finance degree from Westminster College
  • M.S. Cellular and Molecular Biology degree from University of North Carolina at Charlotte
  • B.S. Biology degree from Central Michigan University

“Working in the service of others brings purpose and satisfaction. I am incredibly privileged to have been able to work on medical technologies that save lives, extend and improve the quality of life providing more time for those stricken with disease to spend with family and friends.”

Kurt Andrews

Chief Human Resources Officer

As the Chief Human Resources Officer, Kurt focuses on attracting, developing and rewarding top talent to help fuel Immunomedics growth. This includes leading talent acquisition and development, employee engagement and organizational culture, compensation and benefits, as well as diversity and inclusion programs. Kurt joined Immunomedics in 2018.

Kurt is a seasoned human resources executive with more than 25 years of experience, principally in the Life Sciences and Biotechnology industries. Prior to joining Immunomedics, Kurt was the Senior Vice President of Human Resources at Amicus Therapeutics. He also served as Vice President of Human Resources at Valeritas and PTC Therapeutics earlier in his career.

  • M.A., in Labor and Industrial Relations, University of Illinois at Urbana-Champaign
  • B.A., in Liberal Arts and Sciences, University of Illinois at Urbana-Champaign

“I joined to have a bigger impact on the world, I stay because I love the product, the team, and our culture, and I look forward to having a continued impact on the lives of employees and patients for years to come.

Jared Freedberg

General Counsel and Corporate Secretary

As General Counsel and Corporate Secretary, Jared oversees all aspects of Immunomedics’ Legal, Compliance and Intellectual Property functions. He joined Immunomedics in 2018.

Jared has more than 20 years of legal and business experience in both the pharmaceuticals and pharma services industries. Prior to joining Immunomedics, Jared held simultaneous executive leadership roles for two legal functions at Mallinckrodt Pharmaceuticals -- in Business Development & Licensing as well as General Counsel of the company’s generics division. Before joining Mallinckrodt, Jared spent over fifteen years at Covance and held a variety of senior legal and business roles there, culminating as Vice President of Business Development and Strategy. In addition to his broad legal generalist background, Jared has targeted, negotiated and closed numerous multi-billion strategic growth initiatives and M&A transactions and has also led large scale business transformations, including the global integration of LabCorp’s $6.1 billion acquisition of Covance in 2015.

  • J.D., Duke University School of Law
  • B.A, University of Pennsylvania

"Immunomedics embodies the deep sense of mission that can be found throughout our industry, but here, it’s more intense, more urgent, more tangible, and one of the many reasons I find meaning in my experience every day here."